<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390635</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0616</org_study_id>
    <secondary_id>NCI-2015-00525</secondary_id>
    <secondary_id>2014-0616</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02390635</nct_id>
  </id_info>
  <brief_title>PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>PET/MR, PET/CT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I trial studies how well positron emission tomography (PET)/magnetic
      resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and
      whole body MRI work in finding extramedullary myeloid leukemia in patients with newly
      diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found
      outside of the bone marrow and can be hard to detect with routine bone marrow monitoring,
      such as bone marrow aspirations. Diagnostic procedures, such as PET/MRI, 18F-FDG PET/CT and
      whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with
      newly diagnosed acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To estimate the incidence of extramedullary myeloid leukemia (EML) in patients with newly
      diagnosed acute myeloid leukemia (AML), including acute promyelocytic leukemia (APL), by
      imaging criteria using PET/MR (magnetic resonance), whole body MR, and PET/CT.

      SECONDARY OBJECTIVES:

      I. To qualitatively and quantitatively assess PET/MR and PET/CR that will be performed with
      and without fiducial markers, and to correlate these findings with clinical outcomes of
      treatment response, relapse, and patterns of relapse.

      II. Correlate findings of EML as in the primary objectives with clinical outcomes of
      treatment response, relapse, and patterns of relapse including location of relapse compared
      to site of EML.

      OUTLINE:

      Patients receive gadolinium intravenously (IV) and undergo whole body PET/MRI comprising
      diffusion weighted imaging and 3-dimentional (3D) fast spoiled gradient echo dual echo
      (FSPGR-DE) with and without fiducial markers. Patients then undergo 18F-FDG PET/CT before
      start treatment for acute myeloid leukemia.

      After completion of study, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of extramedullary myeloid leukemia (EML)</measure>
    <time_frame>At time of imaging</time_frame>
    <description>Defined as increased fludeoxyglucose F-18 uptake on positron emission tomography (PET)/computed tomography and increased signal on T2 weighted imaging or diffusion weighted imaging and enhancement in soft tissue on whole body PET/magnetic resonance imaging. Estimates and 95% confidence intervals for the incidence of EML will be reported for each imaging modality based on the exact Clopper-Pearson method.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Promyelocytic Leukemia With PML-RARA</condition>
  <arm_group>
    <arm_group_label>Diagnostic (18F-FDG PET/CT, whole body PET/MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gadolinium IV and undergo whole body PET/MRI comprising diffusion weighted imaging and 3D FSPGR-DE with and without fiducial markers. Patients then undergo 18F-FDG PET/CT before start treatment for acute myeloid leukemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo 18F-FDG PET/CT</description>
    <arm_group_label>Diagnostic (18F-FDG PET/CT, whole body PET/MRI)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diffusion Weighted Imaging</intervention_name>
    <description>Undergo whole body PET/MRI</description>
    <arm_group_label>Diagnostic (18F-FDG PET/CT, whole body PET/MRI)</arm_group_label>
    <other_name>Diffusion Weighted MRI</other_name>
    <other_name>Diffusion-Weighted Magnetic Resonance Imaging</other_name>
    <other_name>Diffusion-Weighted MR Imaging</other_name>
    <other_name>Diffusion-Weighted MRI</other_name>
    <other_name>DW-MRI</other_name>
    <other_name>DWI</other_name>
    <other_name>DWI MRI</other_name>
    <other_name>DWI-MRI</other_name>
    <other_name>MR Diffusion-Weighted Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Undergo 18F-FDG PET/CT</description>
    <arm_group_label>Diagnostic (18F-FDG PET/CT, whole body PET/MRI)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>Fludeoxyglucose (18F)</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (18F-FDG PET/CT, whole body PET/MRI)</arm_group_label>
    <other_name>Gd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo whole body PET/MRI</description>
    <arm_group_label>Diagnostic (18F-FDG PET/CT, whole body PET/MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 18F-FDG PET/CT and whole body PET/MRI</description>
    <arm_group_label>Diagnostic (18F-FDG PET/CT, whole body PET/MRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Three-Dimensional Spoiled Gradient MRI</intervention_name>
    <description>Undergo whole body PET/MRI</description>
    <arm_group_label>Diagnostic (18F-FDG PET/CT, whole body PET/MRI)</arm_group_label>
    <other_name>3-Dimensional Fast Spoiled Gradient</other_name>
    <other_name>3D Fast Spoiled Gradient Recalled MRI</other_name>
    <other_name>3D FSPGR</other_name>
    <other_name>3DFSPGR</other_name>
    <other_name>FSPGR</other_name>
    <other_name>FSPGR MRI</other_name>
    <other_name>SPGR</other_name>
    <other_name>SPGR MRI</other_name>
    <other_name>Three-Dimensional Spoiled Gradient-Echo MR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed AML or acute promyelocytic leukemia (APL)

          -  Women of child bearing potential with negative pregnancy test documented

        Exclusion Criteria:

          -  Patients with contraindications to MR

          -  Patients with a creatinine clearance less than 60

          -  Patients with a known allergy to MR contrast agents

          -  Uncontrollable claustrophobia

          -  Recipients of more than minimal anti-leukemia treatment, with minimal treatment
             defined as: leukapheresis, hydroxyurea, or cytarabine more than 1 g per square meter

          -  Patients with secondary or relapsed AML or APL should be excluded

          -  Patients with known extramedullary leukemia

          -  Positive pregnancy test

          -  Greater than 400 pounds in weight

          -  Patients with uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikas Kundra</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vikas Kundra, MD, PHD</last_name>
    <phone>713-745-2702</phone>
    <email>vkundra@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Kundra</last_name>
      <phone>713-745-2702</phone>
      <email>vkundra@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Vikas Kundra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

